RxDoctor Payments Data

Wolfgang Rodriguez, MD

Family Medicine · Omaha, NENPI 1568519692

Payments from drug & device makers

$995in general payments, 2019–2025

Across 63 payments — averaging $15.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$258
  • Novo Nordisk$130
  • Lilly USA, LLC$97
  • Amgen$80
  • AstraZeneca$60
  • Genentech USA, Inc.$47
  • plus $323 from 14 others

What the payments were for

  • Food & beverage$98499%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$995 in reported general payments places this provider in the 60th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$36,506
Medicare patients
87
Services billed
696

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide177$184,558
FarxigaDapagliflozin Propanediol85$109,659
JardianceEmpagliflozin64$77,372
EliquisApixaban57$74,160
OzempicSemaglutide70$71,619
MounjaroTirzepatide35$38,539
Tresiba Flextouch U-100Insulin Degludec44$26,981
LinzessLinaclotide33$22,742
JanuviaSitagliptin Phosphate16$20,715
SymbicortBudesonide/Formoterol Fumarate47$17,454
JanumetSitagliptin Phos/Metformin Hcl13$14,023
XareltoRivaroxaban15$10,845
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$9,770
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,524
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog22$7,268

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$97$223,096212 claims
AstraZenecaFarxiga, Symbicort, Breztri Aerosphere$60$135,637145 claims
Boehringer IngelheimJardiance, Combivent Respimat$25$82,93875 claims
PfizerEliquis$41$74,16057 claims
Novo NordiskOzempic$130$71,61970 claims
MerckJanuvia, Janumet$26$34,73829 claims
AbbVieLinzess$258$22,74233 claims
GSKTrelegy Ellipta, Arexvy, Arnuity Ellipta$24$16,21239 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →